Expertise in
7
conditions

Dr. Debra A. Patt

Oncology
6204 Balcones Dr, 
Austin, TX 
Accepting New Patients
Offers Telehealth
Expertise in
7
conditions
6204 Balcones Dr, 
Austin, TX 

Overview

Debra Patt is an Oncologist practicing medicine in Austin, Texas.

Dr. Patt is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Squamous Cell Carcinoma of the Anal Canal (SCAC), and Triple-Negative Breast Cancer.

Dr. Patt is board certified in The American Board Of Internal Medicine - Medical Oncology and The American Board Of Preventive Medicine - Clinical Informatics. She is actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 18 clinical trials. Dr. Patt is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Board Certifications

The American Board Of Internal Medicine - Medical Oncology
The American Board Of Preventive Medicine - Clinical Informatics

Fellowships

MD Anderson Cancer Center

Hospital Affiliations

Ascension Seton Medical Center Austin
St David's Medical Center
Ascension Seton Medical Center Austin
Ascension Seton Northwest
Ascension Seton Williamson
Dell Seton Medical Center At The University Of Texas

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sendero
  • HMO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Texas Oncology
6204 Balcones Dr, Austin, TX 78731

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Terminated
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drug: ARX788
Study Phase: Phase 2
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo in Participants With Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer With Molecular Disease Based on Presence of Circulating Tumor DNA After Definitive Therapy (ZEST)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
View 9 Less Clinical Trials

81 Total Publications

Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 16, 2026
Similar Doctors
Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Texas Oncology

6204 Balcones Dr, 
Austin, TX 
 (0.1 miles away)
512-427-9400
Languages Spoken:
English, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Teneriello, MD is a gynecologic oncologist specializing in cancers of the reproductive organs at Ascension Seton in Austin, Texas. Dr. Teneriello delivers personalized care for women. He starts by listening to understand you and your health needs. Then, he works with you to create a cancer care plan that's right for you. Dr. Teneriello provides minimally invasive surgery to treat ovarian, vulvar, endometrial or uterine and cervical cancer. Dr. Teneriello is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Testicular Yolk Sac Tumor. Dr. Teneriello is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Teneriello is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Texas Oncology

12221 Renfert Way, Ste 350, 
Austin, TX 
 (5.5 miles away)
737-610-5200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Loar-Iii is an Oncologist practicing medicine in Austin, Texas. Dr. Loar-Iii is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Bladder Reconstruction. Dr. Loar-Iii is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Loar-Iii is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Texas Oncology

6204 Balcones Dr, 
Austin, TX 
 (0.1 miles away)
512-427-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lynne Knowles is an Oncologist practicing medicine in Austin, Texas. Dr. Knowles is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Malignant Mixed Mullerian Tumor, Endometrial Cancer, Desmoplastic Small Round Cell Tumor, and Vaginal Cancer. Dr. Knowles is board certified in The American Board Of Obstetrics And Gynecology - Gynecologic Oncology and The American Board Of Obstetrics And Gynecology - Obstetrics And Gynecology. Dr. Knowles is currently accepting new patients.

Frequently Asked Questions about Dr. Debra A. Patt

How do I make an appointment with Dr. Debra A. Patt?

You can book an appointment with Dr. Debra A. Patt by calling their office at 512-427-9400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Debra A. Patt a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Debra A. Patt is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Debra A. Patt specialize in?

While Dr. Debra A. Patt is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Squamous Cell Carcinoma of the Anal Canal (SCAC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Debra A. Patt participate in research or clinical trials?

Yes. Dr. Debra A. Patt has published 81 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Debra A. Patt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Debra A. Patt accept my insurance?

Dr. Debra A. Patt accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 512-427-9400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patt's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile